TrialCancer chemotherapy and pharmacology2018

Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial.

Wen Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.